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Previously published guidelines are available that provide
comprehensive recommendations for detecting and prevent-
ing healthcare-associated infections. The intent of this doc-
ument is to highlight practical recommendations in a concise
format designed to assist acute care hospitals in implementing
and prioritizing their central line–associated bloodstream in-
fection (CLABSI) prevention efforts. Refer to the Society for
Healthcare Epidemiology of America/Infectious Diseases So-
ciety of America “Compendium of Strategies to Prevent
Healthcare-Associated Infections” Executive Summary and
Introduction and accompanying editorial for additional
discussion.
section 1: rationale and statements
of concern
1. Patients at risk for CLABSIs in acute care facilities
a. Intensive care unit (ICU) population: The risk of
CLABSI in ICU patients is high. Reasons for this include
the frequent insertion of multiple catheters, the use of spe-
cific types of catheters that are almost exclusively inserted
in ICU patients and associated with substantial risk (eg,
arterial catheters), and the fact that catheters are frequently
placed in emergency circumstances, repeatedly accessed
each day, and often needed for extended periods.1,2
b. Non-ICU population: Although the primary focus of
attention over the past 2 decades has been the ICU setting,
recent data suggest that the greatest numbers of patients
with central lines are in hospital units outside the ICU,
where there is a substantial risk of CLABSI.3-5
2. Outcomes associated with hospital-acquired CLABSI
a. Increased length of hospital stay6-10
b. Increased cost; the non–inflation-adjusted attribut-
able cost of CLABSIs has been found to vary from $3,700
to $29,000 per episode7,10,11
3. Independent risk factors for CLABSI (in 2 or more pub-
lished studies)12-14
Note: femoral catheterization was found to be an independent
risk factor in 1 study.15
a. Factors associated with increased risk
i. Prolonged hospitalization before catheterization
ii. Prolonged duration of catheterization
iii. Heavy microbial colonization at the insertion site
iv. Heavy microbial colonization of the catheter hub
v. Internal jugular catheterization
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vi. Neutropenia
vii. Prematurity (ie, birth at an early gestational age)
viii. Total parenteral nutrition
ix. Substandard care of the catheter (eg, excessive ma-
nipulation of the catheter or reduced nurse-to-patient
ratio)
b. Factors associated with reduced risk
i. Female sex
section 2: strategies to detect
clabsi
1. Surveillance protocol and definitions
a. Use consistent surveillance methods and definitions
to allow comparison with benchmark data
b. Refer to the NHSN Manual: Patient Safety Component
Protocol16 for information on the appropriate surveillance
methodology, including information about blood specimen
collection, and for surveillance definitions of CLABSI. The
relevant sections of the manual are “Identifying Healthcare-
associated Infections (HAI) in NHSN,” “Device-Associated
Module: Methodology,” and “Device-Associated Module:
Central Line-Associated Bloodstream Infection (CLABSI)
Event.”
section 3: strategies to prevent
clabsi
1. Existing guidelines and recommendations
a. Several governmental, public health, and professional
organizations have published evidence-based guidelines
and/or implementation aids regarding the prevention of
CLABSI, including the following:
i. The Healthcare Infection Control Practices Advi-
sory Committee17
ii. The Institute for Healthcare Improvement18 and
iii. Making Health Care Safer, Agency for Healthcare
Research and Quality19
b. The recommendations in this document focus on
central venous catheters (CVCs) unless noted otherwise.
i. These recommendations are not stratified on the
basis of the type of catheter (eg, tunneled, implanted,
cuffed, noncuffed catheter, or dialysis catheter).
ii. These recommendations may not be applicable for
prevention of bloodstream infections with other intra-
vascular devices.
2. Infrastructure requirements
a. An adequately staffed infection prevention and con-
trol program responsible for identifying patients with
CLABSI
b. Information technology to collect and calculate cath-
eter-days as a denominator for computing rates of CLABSI
and patient-days to allow calculation of CVC utilization;
catheter-days from information systems should be vali-
dated against a manual method.
c. Resources to provide appropriate education and
training
d. Adequate laboratory support for timely processing of
specimens and reporting of results
3. Practical implementation
a. Educate physicians, nurses, and other healthcare per-
sonnel about guidelines to prevent CLABSI (eg, with online
and paper versions). These guidelines should be easily
accessible.
b. Develop and implement a catheter insertion checklist.
Educate nurses, physicians, and other healthcare personnel
involved in catheter insertion, regarding the use of the
catheter insertion checklist.
c. Educate healthcare personnel about the insertion and
maintenance of catheters.20 One method is to require
healthcare personnel to complete an educational program
including a posteducation test to ensure their knowledge
and competency before being allowed to insert CVCs.
d. Establish catheter insertion kits/carts containing all
necessary items for insertion.
section 4: recommendations for
implementing prevention and
monitoring strategies
Recommendations for preventing and monitoring CLABSI
are summarized in the following section. They are designed
to assist acute care hospitals in prioritizing and implementing
their CLABSI prevention efforts. Criteria for grading the
strength of the recommendation and quality of evidence are
described in the Table.
Note: Some of the following measures have been combined
into a “prevention bundle” that focuses on catheter insertion
(eg, measures B.2, B.3, B.5, B.6, and C.2).22-24
I. Basic practices for prevention and monitoring of
CLABSI: recommended for all acute care hospitals
A. Before insertion
1. Educate healthcare personnel involved in the insertion,
care, and maintenance of CVCs about CLABSI prevention
(A-II).20,25-28
a. Include the indications for catheter use, appropriate
insertion and maintenance, the risk of CLABSI, and general
infection prevention strategies.
b. Ensure that all healthcare personnel involved in cath-
eter insertion and maintenance complete an educational
program regarding basic practices to prevent CLABSI be-
fore performing these duties.
c. Periodically assess healthcare personnel knowledge of
and adherence to preventive measures.
d. Ensure that any healthcare professional who inserts
a CVC undergoes a credentialing process (as established
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table. Strength of Recommendation and Quality of Evidence
Category/grade Definition
Strength of recommendation
A Good evidence to support a recommendation for use
B Moderate evidence to support a recommendation for use
C Poor evidence to support a recommendation
Quality of evidence
I Evidence from x1 properly randomized, controlled trial
II Evidence from x1 well-designed clinical trial, without
randomization; from cohort or case-control analytic
studies (preferably from 11 center); from multiple
time series; or from dramatic results of uncontrolled
experiments
III Evidence from opinions of respected authorities, based
on clinical experience, descriptive studies, or reports
from expert committees
note. Adapted from the Canadian Task Force on the Periodic Health Examination.21
by the individual healthcare institution) to ensure their
competency before they independently insert a CVC.
B. At insertion
1. Use a catheter checklist to ensure adherence to infection
prevention practices at the time of CVC insertion (B-II).23,29
a. Use a checklist to ensure and document compliance
with aseptic technique.
i. CVC insertion should be observed by a nurse, phy-
sician, or other healthcare personnel who has received
appropriate education (see above), to ensure that aseptic
technique is maintained.
b. These healthcare personnel should be empowered to
stop the procedure if breaches in aseptic technique are
observed.
2. Perform hand hygiene before catheter insertion or ma-
nipulation (B-II).30-33
a. Use an alcohol-based waterless product or antiseptic
soap and water.
i. Use of gloves does not obviate hand hygiene.
3. Avoid using the femoral vein for central venous access
in adult patients (A-I).15,34,35
a. Use of the femoral access site is associated with greater
risk of infection and deep venous thrombosis in adults.
i. Increased risk of infection with femoral catheters
may be limited to overweight adult patients with a body
mass index higher than 28.4.36
ii. Femoral vein catheterization can be done without
general anesthesia in children and has not been asso-
ciated with an increased risk of infection in children.37
b. Several nonrandomized studies show that the sub-
clavian vein site is associated with a lower risk of CLABSI
than is the internal jugular vein, but the risks and benefits
in light of potential infectious and noninfectious compli-
cations must be considered on an individual basis when
determining which insertion site to use.
c. The use of peripherally inserted CVCs is not an evi-
dence-based strategy to reduce the risk of CLABSI.
i. The risk of infection with peripherally inserted
CVCs in ICU patients approaches that with CVCs placed
in the subclavian or internal jugular veins.38
4. Use an all-inclusive catheter cart or kit (B-II).23
a. A catheter cart or kit that contains all necessary com-
ponents for aseptic catheter insertion is to be available and
easily accessible in all units where CVCs are inserted.
5. Use maximal sterile barrier precautions during CVC
insertion (A-I).39-42
a. Use maximal sterile barrier precautions.
i. A mask, cap, sterile gown, and sterile gloves are to
be worn by all healthcare personnel involved in the cath-
eter insertion procedure.
ii. The patient is to be covered with a large sterile
drape during catheter insertion.
b. These measures must also be followed when exchang-
ing a catheter over a guidewire.
6. Use a chlorhexidine-based antiseptic for skin prepara-
tion in patients older than 2 months of age (A-I).43-46
a. Before catheter insertion, apply an alcoholic chlor-
hexidine solution containing a concentration of chlorhex-
idine gluconate greater than 0.5% to the insertion site.
i. The antiseptic solution must be allowed to dry be-
fore making the skin puncture.
ii. Chlorhexidine products are not approved by the
US Food and Drug Administration for children younger
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than 2 months of age; povidone-iodine can be used for
children in this age group.
C. After insertion
1. Disinfect catheter hubs, needleless connectors, and in-
jection ports before accessing the catheter (B-II).47-49
a. Before accessing catheter hubs or injection ports,
clean them with an alcoholic chlorhexidine preparation or
70% alcohol to reduce contamination.
2. Remove nonessential catheters (A-II).50,51
a. Assess the need for continued intravascular access on
a daily basis during multidisciplinary rounds. Remove
catheters not required for patient care.
3. For nontunneled CVCs in adults and adolescents,
change transparent dressings and perform site care with a
chlorhexidine-based antiseptic every 5-7 days or more fre-
quently if the dressing is soiled, loose, or damp; change gauze
dressings every 2 days or more frequently if the dressing is
soiled, loose, or damp (A-I).52,53
4. Replace administration sets not used for blood, blood
products, or lipids at intervals not longer than 96 hours (A-
II).54
5. Perform surveillance for CLABSI (B-II).55
a. Measure unit-specific incidence of CLABSI (CLABSIs
per 1,000 catheter-days) and report the data on a regular
basis to the units, physician and nursing leadership, and
hospital administrators overseeing the units.
b. Compare CLABSI incidence with historical data for
individual units and with national rates (ie, data from the
National Healthcare Safety Network56).
c. CLABSI has been documented in large numbers of
non-ICU patients with CVCs. Surveillance for CLABSI in
these settings requires additional resources.4,5,57
6. Use antimicrobial ointments for hemodialysis catheter
insertion sites (A-I).58-62
a. Povidone-iodine or polysporin ointment should be
applied to hemodialysis catheter insertion sites in patients
with a history of recurrent Staphylococcus aureus CLABSI.
b. Mupirocin ointment should not be applied to the
catheter insertion site due to the risks of mupirocin resis-
tance and damage to polyurethane catheters.
D. Accountability
1. The hospital’s chief executive officer and senior man-
agement are responsible for ensuring that the healthcare sys-
tem supports an infection prevention and control program
that effectively prevents the occurrence of CLABSI.
2. Senior management is accountable for ensuring that an
adequate number of trained personnel are assigned to the
infection prevention and control program.
3. Senior management is accountable for ensuring that
healthcare personnel, including licensed and nonlicensed per-
sonnel, are competent to perform their job responsibilities.
4. Direct healthcare providers (such as physicians, nurses,
aides, and therapists) and ancillary personnel (such as house-
keeping and equipment-processing personnel) are responsible
for ensuring that appropriate infection prevention and con-
trol practices are used at all times (including hand hygiene,
standard and isolation precautions, cleaning and disinfection
of equipment and the environment, aseptic technique when
inserting and caring for CVCs, maximal barrier precautions,
appropriate site selection, and daily assessment of the need
for a CVC).
5. Hospital and unit leaders are responsible for holding
personnel accountable for their actions.
6. The person who manages the infection prevention and
control program is responsible for ensuring that an active
program to identify CLABSIs is implemented, that data on
CLABSIs are analyzed and regularly provided to those who
can use the information to improve the quality of care (eg,
unit staff, clinicians, and hospital administrators), and that
evidence-based practices are incorporated into the program.
7. Individuals responsible for healthcare personnel and pa-
tient education are accountable for ensuring that appropriate
training and educational programs to prevent CLABSIs are
developed and provided to personnel, patients, and families.
8. Personnel from the infection prevention and control
program, laboratory, and information technology depart-
ments are responsible for ensuring that systems are in place
to support the surveillance program.
II. Special approaches for the prevention of CLABSI
Perform a CLABSI risk assessment. These special approaches
are recommended for use in locations and/or populations
within the hospital that have unacceptably high CLABSI rates
despite implementation of the basic CLABSI prevention strat-
egies listed above.
1. Bathe ICU patients older than 2 months of age with a
chlorhexidine preparation on a daily basis (B-II).63
a. Chlorhexidine products are not approved by the US
Food and Drug Administration for children younger than
2 months of age but are used at some institutions for
cleaning CVC insertion sites or as a sponge dressing for
children in this age group.
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b. A povidone-iodine preparation should be used to
clean CVC insertion sites for children younger than 2
months of age, especially low-birth-weight neonates.
2. Use antiseptic- or antimicrobial-impregnated CVCs for
adult patients (A-I).64-70
a. The risk of CLABSI is reduced with some currently
marketed catheters impregnated with antiseptics (eg, chlor-
hexidine-silver sulfadiazine) or antimicrobials (eg, mino-
cycline-rifampin). Consider the use of such catheters in
the following circumstances:
i. Hospital units or patient populations have a
CLABSI rate higher than the institutional goal, despite
compliance with basic CLABSI prevention practices.
ii. Patients have limited venous access and a history
of recurrent CLABSI.
iii. Patients are at heightened risk for severe sequelae
from a CLABSI (eg, patients with recently implanted
intravascular devices, such as a prosthetic heart valve or
aortic graft).
b. These catheters are not approved by the US Food and
Drug Administration for use in children.
i. Preliminary data suggest that antimicrobial-im-
pregnated catheters appear to be safe and may hold
promise for pediatric ICU patients.71,72
3. Use chlorhexidine-containing sponge dressings for
CVCs in patients older than 2 months of age (B-I).73-75
a. Consider the addition of such a dressing in the fol-
lowing circumstances:
i. Hospital units or patient populations have a
CLABSI rate higher than the institutional goal, despite
compliance with an evidence-based prevention bundle.
ii. Patients have limited venous access and a history
of recurrent CLABSI.
iii. Patients are at heightened risk for severe sequelae
from a CLABSI (eg, patients with recently implanted
intravascular devices, such as a prosthetic heart valve or
aortic graft).
b. Do not use chlorhexidine-containing sponge dress-
ings for low-birth-weight neonates.
4. Use antimicrobial locks for CVCs (A-I).76-80
a. Antibiotic locks are created by filling the lumen of
the catheter with a supraphysiologic concentration of an
antimicrobial solution and leaving the solution in place
until the catheter hub is reaccessed. Such an approach can
reduce the risk of CLABSI. Because of concerns regarding
the potential for the emergence of resistance in exposed
organisms and the potential for systemic toxicity from leak-
age of the lock solution into the bloodstream, use anti-
microbial locks as a preventative strategy only for the fol-
lowing:
i. Prophylaxis for patients with limited venous access
and a history of recurrent CLABSI.
ii. Patients who are at heightened risk for severe se-
quelae from a CLABSI (eg, patients with recently im-
planted intravascular devices such as a prosthetic heart
valve or aortic graft).
III. Approaches that should not be considered a routine
part of CLABSI prevention
1. Do not use antimicrobial prophylaxis for short-term or
tunneled catheter insertion or while catheters are in situ (A-
I).81-84
a. Systemic antimicrobial prophylaxis is not recom-
mended.
2. Do not routinely replace CVCs or arterial catheters (A-
I).85-87
a. Routine catheter replacement is not recommended.
3. Do not routinely use positive-pressure needleless con-
nectors with mechanical valves before a thorough assessment
of risks, benefits, and education regarding proper use (B-
II).88-91
a. Routine use of the currently marketed devices that
are associated with an increased risk of CLABSI is not
recommended.
IV. Unresolved issues
1. Nurse-to-patient ratio and use of float nurses in
ICUs92-94
a. Observational studies suggest that there should be a
nurse-to-patient ratio of at least 2 : 1 in ICUs where nurses
are managing patients with CVCs and that the number of
float nurses working in the ICU environment should be
minimized. Formal recommendations await the results of
interventional trials.
2. Intravenous therapy teams for reducing CLABSI rates95
a. Studies have shown that an intravenous therapy team
responsible for insertion and maintenance of peripheral
intravenous catheters reduces the risk of bloodstream in-
fections.96 However, few studies have been performed re-
garding the impact of intravenous therapy teams on
CLABSI rates.
3. Surveillance of other types of catheters (eg, peripheral
arterial catheters)1,2
a. Peripheral arterial catheters have not been included
in most surveillance systems, although they are associated
with a risk of bloodstream infection. Future surveillance
systems may need to include bloodstream infections as-
sociated with these types of catheters.
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4. Estimating catheter-days for determining incidence
density of CLABSI
a. Surveillance can be facilitated in settings with a lim-
ited workforce by estimating the number of catheter-
days.97,98
section 5: performance measures
I. Internal reporting
These performance measures are intended to support internal
hospital quality improvement efforts and do not necessarily
address external reporting needs.
The process and outcome measures suggested here are de-
rived from published guidelines, other relevant literature, and
the opinion of the authors. Report process and outcome mea-
sures to senior hospital leadership, nursing leadership, and
clinicians who care for patients at risk for CLABSI.
A. Process measures (in rank order from highest to lowest
priority)
1. Compliance with CVC insertion guidelines as docu-
mented on an insertion checklist
a. Assess compliance with the checklist in all hospital
settings where CVCs are inserted (eg, ICUs, emergency
department, operating room, radiology, and general wards)
and assign healthcare personnel familiar with catheter care
to this task.
i. For an example of a central catheter checklist, see
the Institute for Healthcare Improvement Web site.99
b. Measure the percentage of CVC insertion procedures
in which compliance with appropriate hand hygiene, use
of maximal sterile barrier precautions, and use of chlor-
hexidine-based cutaneous antisepsis of the insertion site is
documented.
i. Numerator: number of CVC insertions that have
documented the use of all 3 interventions (hand hygiene,
maximal barrier precautions, and chlorhexidine-based
cutaneous antiseptic use) performed at the time of CVC
insertion.
ii. Denominator: number of all CVC insertions.
iii. Multiply by 100 so that the measure is expressed
as a percentage.
2. Compliance with documentation of daily assessment re-
garding the need for continuing CVC access
a. Measure the percentage of patients with a CVC for
whom there is documentation of daily assessment.
i. Numerator: number of patients with a CVC for
whom there is documentation of daily assessment.
ii. Denominator: number of patients with a CVC.
iii. Multiply by 100 so that the measure is expressed
as a percentage.
3. Compliance with cleaning of catheter hubs and injection
ports before they are accessed
a. Assess compliance through observations of practice.
i. Numerator: number of times that a catheter hub
or port is observed to be cleaned before being accessed.
ii. Denominator: number of times a catheter hub or
port is observed to be accessed.
iii. Multiply by 100 so that the measure is expressed
as a percentage.
4. Compliance with avoiding the femoral vein site for CVC
insertion in adult patients
a. Perform point prevalence surveys or use information
collected as part of the central line insertion checklist to
determine the percentage of patients whose CVCs are in
the femoral vein versus the subclavian or internal jugular
veins.
b. Calculate the percentage of patients with a femoral
vein catheter.
i. Numerator: number of patients with a CVC in the
femoral vein.
ii. Denominator: total number of patients with a CVC
in unit population being assessed.




a. Use National Healthcare Safety Network definitions.
i. Numerator: number of CLABSIs in each unit as-
sessed (using National Healthcare Safety Network
definitions).
ii. Denominator: total number of catheter-days in
each unit assessed (using National Healthcare Safety
Network definitions).
iii. Multiply by 1,000 so that the measure is expressed
as number of CLABSIs per 1,000 catheter-days.
iv. Risk adjustment: stratify CLABSI rates by type of
patient-care unit.100-102
(a) Report comparisons based on historical data
and National Healthcare Safety Network data, if
available.56
II. External reporting
There are many challenges in providing useful information
to consumers and other stakeholders while preventing un-
intended adverse consequences of public reporting of health-
care-associated infections.103 Recommendations for public re-
porting of healthcare-associated infections have been
provided by the Healthcare Infection Control Practices Ad-
visory Committee,104 the Healthcare-Associated Infection
Working Group of the Joint Public Policy Committee,105 and
the National Quality Forum.106
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A. State and federal requirements
1. Hospitals in states that have mandatory reporting re-
quirements for CLABSI must collect and report the data re-
quired by the state.
2. For information on state and federal requirements, con-
tact your state or local health department.
B. External quality initiatives
1. Hospitals that participate in external quality initiatives
or state programs must collect and report the data required
by the initiative or the program.
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